
FDA Fast-Tracks Novel ADC in Cervical Cancer
The FDA has granted fast track designation to ADRX-0706 for the treatment of advanced cervical cancer. ADRX-0706 is a Nectin-4-targeted antibody-drug conjugate (ADC). The agent is being evaluated in a phase 1a/b clinical trial (NCT06036121) for the …